| Patent application number | Description | Published |
| 20100273855 | COMPOSITIONS AND METHODS OF TREATING CANCER - The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma. | 10-28-2010 |
| 20110160288 | OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS - The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody. The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5. | 06-30-2011 |
| 20110160293 | PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS - Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them. | 06-30-2011 |
| 20110237518 | METHOD FOR TREATING OR PREVENTING BLADDER CANCER USING THE DEPDC1 POLYPEPTIDE - The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer. | 09-29-2011 |
| 20110251090 | PANCREATIC CANCER RELATED GENE TTLL4 - The present invention relates to the roles played by TTLL4 genes in pancreatic cancer carcinogenesis and features a method for treating or preventing pancreatic cancer by administering a double-stranded molecule against one or more of the TTLL4 genes or a composition, vector or cell containing such a double stranded molecule. Also, disclosed are methods of identifying compounds for treating and preventing pancreatic cancer, using as an index their effect on the over-expression of TTLL4 in the pancreatic cancer cell. | 10-13-2011 |
| 20110262463 | SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS - The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer. | 10-27-2011 |
| 20110263679 | C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS - Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them. | 10-27-2011 |
| 20110319280 | ECT2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND ESOPHAGEAL CANCER - The invention features methods for detecting lung cancer or esophageal cancer, by detecting over-expression of ECT2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing lung cancer or esophageal cancer, based on the over-expression of ECT2 in the lung cancer or esophageal cancer, the cell proliferation function of ECT2. Also, provided are a method for treating lung cancer or esophageal cancer by administering a double-stranded molecule against the ECT2 gene or an antibody against ECT2 protein. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. | 12-29-2011 |
| 20120010266 | TBC1D7 AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER - The present invention relates to the roles played by the TBC1D7 genes in cancer, in particular, lung cancer or esophageal cancer, or carcinogenesis and features a method for treating and/or preventing cancer, in particular, lung cancer or esophageal cancer by administering a double-stranded molecule against one or more of the TBC1D7 genes or a composition, vector or cell containing such a double stranded molecule. The present invention also features methods for diagnosing lung or assessing/determining the prognosis of a patient with lung, especially NSCLC or SCLC, or esophageal cancer, using one or more over-expressed genes selected from among TBC1D7. To that end, TBC1D7 may serve as a novel biomarker for lung cancer or esophageal cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung or esophageal cancer, using as an index for their effect on the over-expression of one or more of TBC1D7 in the lung cancer or esophageal cancer. | 01-12-2012 |
| 20120022131 | BREAST CANCER RELATED GENE RQCD1 - The present invention provides methods for detecting and diagnosing cancer, such methods involving the determination of the expression level of the RQCD1, GIGYF1 or GIGYF2 genes. These genes were discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer and methods for treating cancer. Moreover, the present invention provides siRNAs targeting the RQCD1, GIGYF1 and/or GIGYF2 genes, all of which are suggested to be useful in the treatment of cancer. | 01-26-2012 |
| Patent application number | Description | Published |
| 20100093390 | Mobile Radio Device - The present invention provides a portable wireless device that allows for a reduction in size of a body thereof through effective use of space inside the body by suppressing gain degradation of antennae. The portable wireless device includes: a body; a first communication unit | 04-15-2010 |
| 20100130140 | PORTABLE WIRELESS DEVICE - A mobile wireless device enables effective use of space in a case while reducing degradation of ah antenna gain and maintaining communication quality even if a plurality of antennas having different frequency bands are arranged close to one another. A magnetic antenna has a first switch unit, a second switch unit, and a concentrated constant circuit which are added to a wiring pattern at the side near to a main antenna, so that a first path and a second path can be selected. Under a predetermined condition, a CPU controls the first switch and the second switch to electrically connect a terminal (A | 05-27-2010 |
| 20110199283 | PORTABLE ELECTRONIC DEVICE - A portable electronic device is provided that is capable of reducing the degradation in the characteristic of an antenna caused by the orientation direction of the antenna being fixed. The device includes a circuit board disposed in the vicinity of an antenna, a conductive switch terminal that is provided to the circuit board and detects an operation to an operation unit, a reference potential part provided to the circuit board to be opposite to the switch terminal, a conductive part provided to the circuit board to be opposite to the antenna, and a switch unit capable of switching whether the reference potential part and the conductive part are electrically connected. | 08-18-2011 |
| 20110273357 | PORTABLE TERMINAL - Provided is a portable terminal wherein reduction of an antenna gain can be suitably suppressed. The portable terminal is provided with a circuit section ( | 11-10-2011 |
| 20120019996 | PORTABLE TERMINAL - Provided is a portable terminal wherein reception sensitivity can be easily adjusted. A portable terminal is provided with an operating section side case section ( | 01-26-2012 |
| Patent application number | Description | Published |
| 20090207704 | Recording apparatus, server apparatus, recording method, program, and storage medium - A data recording apparatus recording data of a CD on an HDD in a manner such that the content of record in the CD is faithfully accounted for and shortening an operation time for a synchronized ripping operation. When the data recording apparatus reads, from the CD, track data managed by track, according to TOC, and records the track data onto the HDD, the data recording apparatus recognizes data unrecorded on the HDD, from among the track data recorded on the CD. This recognition process is automatically performed based on the TOC read from the CD, and album information replayed using the TOC and held by the HDD. The recording apparatus reproduces and outputs only the unrecorded data from the CD based on the recognition result concerning the unrecorded data. In this way, the data already recorded on the HDD is not transferred from the CD to the HDD. The operation time for the synchronized ripping operation is reduced accordingly. | 08-20-2009 |
| 20110109985 | RECORDING APPARATUS, SERVER APPARATUS, RECORDING METHOD, PROGRAM, AND STORAGE MEDIUM - A data recording apparatus recording data of a CD on an HDD in a manner such that the content of record in the CD is faithfully accounted for and shortening an operation time for a synchronized ripping operation. When the data recording apparatus reads, from the CD, track data managed by track, according to TOC, and records the track data onto the HDD, the data recording apparatus recognizes data unrecorded on the HDD, from among the track data recorded on the CD. This recognition process is automatically performed based on the TOC read from the CD, and album information replayed using the TOC and held by the HDD. The recording apparatus reproduces and outputs only the unrecorded data from the CD based on the recognition result concerning the unrecorded data. In this way, the data already recorded on the HDD is not transferred from the CD to the HDD. The operation time for the synchronized ripping operation is reduced accordingly. | 05-12-2011 |